[{"address1": "Fitzwilliam Court", "address2": "1st Floor Leeson Close", "city": "Dublin", "zip": "D02 YW24", "country": "Ireland", "phone": "353 1 669 4820", "website": "https://www.iterumtx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.", "fullTimeEmployees": 14, "maxAge": 86400, "priceHint": 4, "previousClose": 1.15, "open": 1.19, "dayLow": 1.15, "dayHigh": 1.3207, "regularMarketPreviousClose": 1.15, "regularMarketOpen": 1.19, "regularMarketDayLow": 1.15, "regularMarketDayHigh": 1.3207, "beta": 2.28, "forwardPE": -1.2277228, "volume": 355546, "regularMarketVolume": 355546, "averageVolume": 140882, "averageVolume10days": 153430, "averageDailyVolume10Day": 153430, "bid": 1.18, "ask": 1.28, "bidSize": 100, "askSize": 100, "marketCap": 20528076, "fiftyTwoWeekLow": 0.622, "fiftyTwoWeekHigh": 2.5, "fiftyDayAverage": 1.437, "twoHundredDayAverage": 1.380425, "currency": "USD", "enterpriseValue": 22868058, "floatShares": 16235045, "sharesOutstanding": 16554900, "sharesShort": 1246632, "sharesShortPriorMonth": 1197109, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0753, "heldPercentInsiders": 0.01454, "heldPercentInstitutions": 0.056479998, "shortRatio": 10.05, "shortPercentOfFloat": 0.076799996, "impliedSharesOutstanding": 16554900, "bookValue": -0.373, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -35583000, "trailingEps": -2.64, "forwardEps": -1.01, "lastSplitFactor": "1:15", "lastSplitDate": 1660780800, "enterpriseToEbitda": -0.522, "52WeekChange": 0.15887845, "SandP52WeekChange": 0.26238096, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "ITRM", "underlyingSymbol": "ITRM", "shortName": "Iterum Therapeutics plc", "longName": "Iterum Therapeutics plc", "firstTradeDateEpochUtc": 1527255000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "2a47ad90-f2ae-3045-b6c4-2f53ded8d73b", "messageBoardId": "finmb_318354064", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.24, "targetHighPrice": 7.0, "targetLowPrice": 6.0, "targetMeanPrice": 6.5, "targetMedianPrice": 6.5, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 2, "totalCash": 18214000, "totalCashPerShare": 1.1, "ebitda": -43780000, "totalDebt": 20554000, "quickRatio": 1.025, "currentRatio": 1.071, "returnOnAssets": -0.72514, "returnOnEquity": -5.5568, "freeCashflow": -26696876, "operatingCashflow": -42823000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]